A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer

Brief description of study

The purpose of this study is to: • Test the safety of the study drug (olaparib), see how well the drug works, and see how your body handles the drug. • To see if the study drug helps patients live longer. Olaparib (MK-7339), also known as Lynparza™, has been approved by certain health authorities for the treatment of various cancers, however, it may not be approved for your exact type of cancer in your country. You may be able to join this study if you have previously treated advanced cancer that is positive for homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD). HRRm is a process used by cells to accurately repair harmful breaks that occur on both strands of DNA, known as double-strand breaks. Your HRRm and HRD status will be determined using a comprehensive cancer panel test that analyzes the sequence of cancer-related genes.

Clinical Study Identifier: s18-01650
ClinicalTrials.gov Identifier: NCT03742895

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.